Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.

[1]  James B. Mitchell,et al.  Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy , 2008, Circulation.

[2]  David A. Kass,et al.  Tackling heart failure in the twenty-first century , 2008, Nature.

[3]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[4]  D. Kass,et al.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation. , 2007, Circulation research.

[5]  Anindita Das,et al.  Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[6]  David M. Harris,et al.  Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat. , 2007, American journal of physiology. Heart and circulatory physiology.

[7]  M. Mongillo,et al.  Protein Kinase G Phosphorylates Cav1.2 α1c and β2 Subunits , 2007, Circulation research.

[8]  S. Bangalore,et al.  A Critical Review of the Evidence , 2007 .

[9]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study , 2007, Circulation.

[10]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[11]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[12]  D. Kass,et al.  Phosphodiesterase regulation of nitric oxide signaling. , 2007, Cardiovascular research.

[13]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[14]  D. Kass,et al.  Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. , 2007, Journal of the American College of Cardiology.

[15]  O. Brodde.  β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[17]  Timothy E. Hewett,et al.  Pharmacological- and Gene Therapy–Based Inhibition of Protein Kinase Cα/β Enhances Cardiac Contractility and Attenuates Heart Failure , 2006 .

[18]  D. Dobrev,et al.  Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. , 2006, Biochemical and biophysical research communications.

[19]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[20]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[21]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[22]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[23]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[24]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[25]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[26]  T. Hewett,et al.  PKC-α regulates cardiac contractility and propensity toward heart failure , 2004, Nature Medicine.

[27]  C. Deschepper,et al.  Expression of Constitutively Active Guanylate Cyclase in Cardiomyocytes Inhibits the Hypertrophic Effects of Isoproterenol and Aortic Constriction on Mouse Hearts* , 2003, Journal of Biological Chemistry.

[28]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[29]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[30]  A. Shah,et al.  Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.

[31]  J. Beavo,et al.  Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance , 2001, Circulation.

[32]  Y. Takeishi,et al.  PKC translocation without changes in Gαq and PLC-β protein abundance in cardiac hypertrophy and failure. , 1999, American Journal of Physiology. Heart and Circulatory Physiology.

[33]  Y. Takeishi,et al.  PKC translocation without changes in Gαq and PLC-β protein abundance in cardiac hypertrophy and failure. , 1999, American Journal of Physiology. Heart and Circulatory Physiology.

[34]  D. Kass,et al.  Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. , 1998, Circulation.

[35]  O. Brodde.  Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. , 2007, Naunyn-Schmiedeberg's archives of pharmacology.

[36]  Andrew N. Carr,et al.  Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. , 2006, Circulation.

[37]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.

[38]  T. Hewett,et al.  PKC-alpha regulates cardiac contractility and propensity toward heart failure. , 2004, Nature medicine.

[39]  P. Wright,et al.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.